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Aims Cardiac optical mapping is the gold standard for measuring complex electrophysiology in ex vivo heart preparations.
However, new methods for optical mapping in vivo have been elusive. We aimed at developing and validating an ex-




First, we characterized ex vivo the excitation-ratiometric properties during pacing and ventricular fibrillation (VF) of
two near-infrared voltage-sensitive dyes (di-4-ANBDQBS/di-4-ANEQ(F)PTEA) optimized for imaging blood-perfused
tissue (n = 7). Then, optical-fibre recordings in Langendorff-perfused hearts demonstrated that ratiometry permits the
recording of optical action potentials (APs) with minimal motion artefacts during contraction (n = 7). Ratiometric opti-
cal mapping ex vivo also showed that optical AP duration (APD) and conduction velocity (CV) measurements can be
accurately obtained to test drug effects. Secondly, we developed a percutaneous dye-loading protocol in vivo to per-
form high-resolution ratiometric optical mapping of VF dynamics (motion minimal) using a high-speed camera system
positioned above the epicardial surface of the exposed heart (n = 11). During pacing (motion substantial) we recorded
ratiometric optical signals and activation via a 2D fibre array in contact with the epicardial surface (n = 7). Optical APs
in vivo under general anaesthesia showed significantly faster CV [120 (63–138) cm/s vs. 51 (41–64) cm/s; P = 0.032]
and a statistical trend to longer APD90 [242 (217–254) ms vs. 192 (182–233) ms; P = 0.095] compared with ex vivo
measurements in the contracting heart. The average rate of signal-to-noise ratio (SNR) decay of di-4-ANEQ(F)PTEA
in vivo was 0.0671 ± 0.0090 min-1. However, reloading with di-4-ANEQ(F)PTEA fully recovered the initial SNR. Finally,
toxicity studies (n = 12) showed that coronary dye injection did not generate systemic nor cardiac damage, although
di-4-ANBDQBS injection induced transient hypotension, which was not observed with di-4-ANEQ(F)PTEA.
....................................................................................................................................................................................................
Conclusions In vivo optical mapping using voltage ratiometry of near-infrared dyes enables high-resolution cardiac electrophysiol-
ogy in translational pig models.
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For decades, the goal of cardiac electrophysiology procedures has been
to obtain accurate information regarding cardiac electrical activation
during both normal sinus rhythm and various types of arrhythmias.1–4
Current clinical approaches map cardiac electrical activity from the en-
docardial or epicardial surface of the heart using electrical signals ac-
quired from bipolar or unipolar electrograms.3–5 This electrical data can
then be integrated with 3D anatomical surfaces to facilitate localization
of specific activation patterns.6,7 However, neither bipolar nor unipolar
recordings enable the measurement of action potentials (APs) from the
myocardium. Bipolar signals can estimate activation times, while unipolar
signals can estimate both activation and repolarization times.8,9
Furthermore, these estimations become more difficult in regions with
poor signal quality that are often associated with scarred tissue.10,11
To date, the best method of probing cellular electrophysiology in the
whole heart is optical mapping.12 Optical mapping uses high-speed cam-
eras or optical sensors to record fluorescence changes on the epicardial
or endocardial surface of isolated Langendorff-perfused hearts, following
injection of excitation-contraction uncouplers and voltage- or calcium-
sensitive dyes.13 This approach measures APs or calcium transients at
high spatiotemporal resolution and has led to important milestones in
the understanding of cardiac electrophysiology and the mechanisms of
complex arrhythmias.2,14 Despite the immensely fruitful impact of such
ex vivo optical mapping studies, maintaining the native connections to the
nervous and endocrine systems, may be critical to the study of certain
arrhythmias.15 However, to make progress in this area, two key issues
need to be addressed: (i) the use of excitation-contraction uncouplers
to minimize motion artefacts in fluorescence signals is not a viable option
in vivo; and (ii) voltage-sensitive dyes might be toxic to vital organs, which
has not been thoroughly investigated in vivo.
Here, we aimed at developing and validating an experimental method
for performing in vivo optical mapping in a pig animal model with high sim-
ilarity in heart size, anatomy and physiology to humans. To address the
two aforementioned issues, we first characterized the excitation-
ratiometric properties and ex vivo performance during ventricular fibrilla-
tion (VF) of two near-infrared voltage-sensitive dyes, di-4-ANBDQBS
and di-4-ANEQ(F)PTEA, with the use of blebbistatin. On the basis of
these results, we built and tested ex vivo an optical mapping system using
fibre-optic technology and voltage ratiometry without the use of blebbis-
tatin. We then established an intracoronary dye-loading procedure in
vivo and validated systems that perform ratiometric optical mapping of
both induced VF episodes, and APs and activation waves during electrical
pacing. Finally, we conducted comprehensive toxicity analyses following
percutaneous intracoronary dye injection.
2. Methods
A detailed description of the different Methods sections is provided in
the Supplementary material online.
2.1 Study design
We used three different animal groups (large-white pigs, 60–80 kg) as
follows: Group I (n = 14) consisted of pigs undergoing cardiac excision
to characterize the ratiometric properties of di-4-ANBDQBS and di-4-
ANEQ(F)PTEA, and to develop optical mapping instrumentation for
imaging the contracting heart; Group II (n = 18) consisted of pigs under-
going open-chest surgery and percutaneous dye loading into the left
anterior descending (LAD) coronary artery to test and validate instru-
mentation from Group I, as well as to measure deterioration of fluores-
cence signals over time; and Group III (n = 12) consisted of pigs
undergoing a minimally invasive percutaneous approach to test dye-
related toxicity in the vital organs. All surgical procedures (Group I and
Group II animals) were performed under general anaesthesia. Pigs were
pre-medicated with a combination of intramuscular Xylazine (2 mg/kg
i.m.) and Midazolam (0.5 mg/kg i.m.). Anaesthesia was induced with intra-
venous Ketamine (20 mg/kg i.v.). After intubation animals were mechani-
cally ventilated and anaesthesia was maintained by a combination of
Fentanyl (0.010 mg/kg/h i.v.) and Sevoflurane (2.5%). In interventional
procedures (Group III animals), anaesthesia was maintained with contin-
uous intravenous infusion of Ketamine (2 mg/kg/h), Fentanyl (0.005 mg/
kg/h i.v.), and Midazolam (0.2 mg/kg/h) to avoid any bias in toxicity assess-
ment related to the cardio-protective effects of Sevoflurane administra-
tion.16 Pigs were euthanized with thiopental (10 mg/kg iv).
The experimental studies were conducted in accordance with institu-
tional guidelines and regulations [National (ECC/566/2015, RD53/2013)
and European (2010/63/EU) guidelines for the care and use of laboratory
animals]. All in vivo experimental procedures were evaluated and granted
by the Institutional Animal Care and Use Committee (IACUC) of CNIC
and the Local Competent Authority.
2.2 Ratiometric optical mapping in the
Langendorff-perfused pig heart
Excised hearts were cleaned, cannulated through the aorta and then
connected to a constant-flow Langendorff-perfusion apparatus as
reported elsewhere.12 First, three pig hearts were used to investigate
the ratiometric properties of two near-infrared voltage-sensitive dyes,
di-4-ANBDQBS and di-4-ANEQ(F)PTEA (University of Connecticut
School of Medicine, Farmington, CT, USA) optimized for imaging blood-
perfused tissue.17,18 After an initial 20 min of perfusion following cannula-
tion, the dye was injected at a short distance upstream from the aortic
cannula for coronary perfusion. Hearts were loaded with 750mL (di-4-
ANBDQBS) or 500mL (di-4-ANEQ(F)PTEA) of stock dye solution
(10 mg of di-4-ANBDQBS/di-4-ANEQ(F)PTEA dissolved in 3 mL of
pure ethanol) diluted in 10 mL of Tyrode’s solution, delivered slowly
over a 1-min period, without recirculation. After dye loading, the perfus-
ate was replaced with fresh Tyrode’s solution containing 10 lM blebbis-
tatin (part #: 674289-55-5; Cayman Chemical Company, Ann Arbor, MI,
USA) to minimize contraction.
For imaging, we used two red and two blue light-emitting-diodes
(LEDs; part #: CBT-90 Red and CBT-90 Blue; Luminus Devices Inc.,
Woburn, MA, USA) to excite dye-loaded tissue (Figure 1A). The excita-
tion light from each LED was passed through a plano-convex lens (L1
and L2; part #: LA1951; Thorlabs Inc., Newton, NJ, USA) and an excita-
tion filter. Various red and blue excitation filters were used to optimize
excitation-ratiometry measurements (i.e. to maximize alterations in
emission intensity of opposite polarity). In the adult pig myocardium, we
found a substantial shift for both di-4-ANBDQBS and di-4-
ANEQ(F)PTEA at 640 nm vs. 480 nm (F1 and F2; part #: ZET642/
20X passing 632–652 nm and AT480/30X passing 465—495 nm
Chroma Technology Corp, Bellows Falls, VT, USA). Dichroic mirrors
were used to merge the red and blue lights into one path (D1; part #:
T505LPXR passing above 505 nm and reflecting below 505 nm; Chroma
Technology Corp.). Fluorescence emission light from the heart was
passed through a custom-made emission filter (F3; part #: ET700LP pass-
ing above 700 nm; Chroma Technology Corp.) and then collected with a








































































































fast camera lens (L3; part #: DO-1795; Navitar Inc., Rochester, NY,
USA). Fluorescence images were taken with a high-speed electron-mul-
tiplying charge-coupled device camera running at 400/500 fps (Evolve
128 EMCCD camera; 128 128 pixels; Photometrics, AZ, USA).
Excitation ratiometry was achieved by synchronizing the red and blue
LEDs with the camera frame exposure.
Seven pig hearts were used to test ratiometric optical mapping in the
isolated Langendorff-perfused heart loaded with di-4-ANBDQBS (n = 2)
or di-4-ANEQ(F)PTEA (n = 5) without the use of blebbistatin. The optical
mapping system outlined in Figure 1A was modified to image fluorescence
via an optical-fibre array pressed against the epicardial surface (Figure 1B).
A 4 4 array (interfibre distance: 4 mm) of 1500mm plastic optical fibres
was constructed (part #: 02-535; Edmund Optics Inc., Barrington, NJ,
USA) and an additional dichroic mirror was used to merge the excitation
and emission light into one path (D2; part #: FF685-Di02 passing above
685 nm and reflecting below 685 nm; Semrock Inc., Rochester, NY, USA).
Both excitation and emission lights were transmitted down the same opti-
cal fibre. Sample optical recordings were also obtained with a catheter-
compatible 500mm plastic optical fibre (part #: 02-532; Edmund Optics
Inc.) to increase the translational impact. To zoom in on the proximal end
of the smaller fibre, an additional lens was used (L3; part #: DO-1795;
Navitar Inc.). Furthermore, the pig hearts loaded with di-4-ANEQ(F)PTEA
were used to measure the changes in AP duration (APD) and conduction
velocity (CV) due to excitation-contraction uncoupling with blebbistatin.
2.3 Animal preparation for in vivo optical
mapping
All animals underwent open-chest surgery to expose the ascending
aorta and the anterior region of the heart. An electrosurgical blade was
used to seal blood vessels for the purpose of haemostasis, which was
confirmed to be stable for 15 min before the administration of a single
bolus of unfractionated heparin (130 IU/kg i.v.) at the onset of percutane-
ous coronary instrumentation. Then, an AL-2 6-French guiding catheter
was used to cannulate the main left coronary artery, while coronary
anatomy was examined via two angiographic projections. The tip of the
catheter was positioned into the proximal LAD coronary artery with the
use of a 0.014-inch guide. Dye loading was tested using two strategies:
(1) Dye loading in the absence of coronary blood flow (n = 5): An occlusion
balloon catheter (Helios, LightLab Imaging Inc., Westford, MA, USA) was
positioned and inflated at the origin of the LAD coronary artery. The in-
ternal lumen of the balloon was used to inject 1.5 mL of stock dye solu-
tion diluted in 30 mL of saline and then delivered slowly over a 40-s
period. A continuous infusion of amiodarone (100 mg/h) was adminis-
tered 15 min before balloon occlusion and stopped 5 min after deflating
the balloon to decrease the risk of ventricular arrhythmia.
(2) Dye loading in the presence of regular coronary blood flow (n = 13):
Di-4-ANBDQBS (n = 4) was injected using the same dye mixture over
a 40-s period. Di-4-ANEQ(F)PTEA (n = 9) loading was performed using
1 mL of stock dye solution diluted in 30 mL of saline and then delivered
slowly over a 50-s period. No amiodarone perfusion was used with this
approach.
The ratiometric optical mapping systems developed for isolated
Langendorff-perfused heart preparations were applied in vivo following
dye injection (Figure 1C and D).
2.4 Toxicity assessment protocol
Group III animals were divided into three subgroups: (i) di-4-
ANBDQBSþsolvent injection (n = 4), (ii) di-4-ANEQ(F)PTEAþsolvent
injection (n = 4), and (iii) solvent injection (n = 4). Intracoronary dye de-
livery was performed in the same manner as dye loading in the presence
of coronary blood flow. Solvent injection was performed using 1.5 mL of
pure ethanol (dye solvent) diluted in 30 mL of saline and delivered over a
40-s period. Electrocardiogram (ECG) recordings (see Supplementary
material online, Figure S1), blood pressure, and pulsioximetry were digi-
tally monitored and acquired at 1 kHz throughout the procedure and for
30 more minutes thereafter (LabSystem-Pro recording system, Boston
Scientific, Lowell, MA, USA).
All animals underwent blood testing to obtain toxicity biomarkers re-
lated to vital organs using the following sequential timeline: baseline
(30 min before the procedure), 30 min, 90 min, 12 h, 24 h, 48 h, 72 h,
7 days and 10 days after coronary dye/solvent injection.
Cardiac magnetic resonance (CMR) studies were performed to deter-
mine any overt structural and functional alterations at baseline, 90 min af-
ter dye/solvent injection and after 10 days as a follow-up. All studies
were performed using a Philips Achieva 3T-Tx whole-body scanner
(Philips Healthcare, Best, The Netherlands) equipped with a 32-element
phased array cardiac coil. The baseline protocol included Cine, T2
GraSE and T1 mapping sequences without contrast administration. CMR
sequences after 90 min and 10 days also included isotropic 3D delayed-
enhancement and post-contrast T1 mapping to assess diffuse cardiac
damage due to dye/solvent injection.
2.5 Statistical analysis
All statistical comparisons were performed in hearts loaded with di-4-
ANEQ(F)PTEA. Ratiometric optical signals for APD and CV compari-
sons were obtained from four fibres per heart. APD values used were
the average of APD90 measurements of five consecutive APs during elec-
trical pacing at 400 ms cycle length (CL). The Wilcoxon Signed Rank test
was used for statistical comparisons before and after blebbistatin perfu-
sion. The Mann–Whitney U test was used for statistical comparisons be-
tween in vivo and ex vivo data. A two-way repeated measures analysis of
variance (ANOVA) was used for toxicity comparisons among subgroups
over the follow-up period. Differences were considered statistically sig-
nificant at P < 0.05.
3. Results
3.1 Ratiometric properties of di-4-
ANBDQBS and di-4-ANEQ(F)PTEA
Our prior experience in Langendorff-perfused pig heart experiments
showed that the near-infrared ‘second-generation’ voltage-sensitive dye,
di-4-ANBDQBS, loads easily and without the use of additional agents
such as pluronic F-127.18 Hence, di-4-ANBDQBS was used for the initial
phase of this study. After an initial round of ex vivo and in vivo experiments
with di-4-ANBDQBS, we transitioned to using a near-infrared ‘third-gen-
eration’ fluorinated voltage-sensitive dye, di-4-ANEQ(F)PTEA, with im-
proved photostability and solubility.17 An experimental flow-chart is
shown in Figure 2A.
Ratiometric dyes characteristically display a spectral shift in their exci-
tation or emission spectra. After arresting contraction with blebbistatin,
we found that both di-4-ANBDQBS and di-4-ANEQ(F)PTEA showed a
substantial shift at480 nm vs.640 nm (Figure 2B). The numerator and
denominator AP signals were obtained by exciting tissue at 480 and
640 nm, respectively. The same AP led to alterations in emission inten-
sity of opposite polarity. Normalized transmembrane voltage fluores-
cence intensity maps, using the ratio signal enabled the tracking and














































.visualization of the activation and repolarization fronts propagating
across the epicardium (Figure 2C and see Supplementary material online,
Movies S1 and S2). Ratiometric imaging of complex activation patterns
during VF also showed alterations in emission intensity of opposite po-
larity for each excitation potential (Figure 2D and see Supplementary ma-
terial online, Movies S3 and S4). The ratio signal also enabled the
generation of dominant frequency (DF) maps (Figure 2D).
3.2 Voltage ratiometry ex vivo enables
optical mapping in the contracting heart
Since motion artefacts display a similar change and the same polarity in
fluorescence for 480 and 640 nm excitations, taking the ratio of the
numerator to denominator signal has the potential to significantly reduce
motion artefacts in the contracting heart not arrested with blebbistatin.
A experimental flow-chart is shown in Figure 3A.
A 2D optical-fibre array (4 4) was pressed against the epicardial sur-
face of the Langendorff-perfused pig heart (Figure 3B and see
Supplementary material online, Movie S5) after di-4-ANBDQBS/di-4-
ANEQ(F)PTEA loading. Sample numerator and denominator AP signals
are shown in Figure 3B during 400 ms CL pacing. Sample activation maps
illustrating wave front propagation are also shown in Figure 3C (see
Supplementary material online, Movie S6) (di-4-ANEQ(F)PTEA).
Although the rapid increase (numerator) and decrease (denominator)
corresponding to the phase-zero depolarization were discernible, repo-
larization signals were highly distorted by motion artefacts. Taking the ra-
tio of these signals significantly reduced artefacts, uncovering the AP
repolarization (Figure 3B).
In Langendorff-perfused hearts loaded with di-4-ANEQ(F)PTEA
(n = 5), ratiometric optical-fibre data before and after 30 min of blebbis-
tatin administration in the perfusate (Figure 3B and C) showed a significant
prolongation of APD [median (inter-quartile range), APD90 192 (182–
233) ms vs. 227 (210–254) ms, respectively; P = 0.031, Figure 3D] and a
decrease in CV [51 (41–64) cm/s vs. 38 (32–48) cm/s, respectively;
P = 0.031, Figure 3E]. A highly flexible and catheter-compatible plastic op-
tical fibre (500 mm diameter) also showed APs in the contracting heart
with minimal motion artefacts (Figure 3F).
3.3 Di-4-ANBDQBS and di-4-
ANEQ(F)PTEA loading in vivo
Fluorescence imaging of the exposed heart was carried out at relatively
high frame rates (300 fps) to capture fluorescence coronary angiograms
and to assess the efficacy of dye-loading protocols. A higher spatial
Figure 1 In vivo optical mapping systems. (A) Schematic representation of the system built to optically map the exposed heart in the open-chest pig dur-
ing dye loading and ventricular fibrillation (dye-loading region highlighted purple). (B) Schematic representation of the modified system using an optical-fi-
bre array to measure action potentials during regular contraction. (C) 3D representation of the system in (A) during an in vivo experiment. (D) 3D
representation of the system in (B) during an in vivo experiment.



















..resolution CMOS camera (complementary metal–oxide–semiconduc-
tor) was used instead of the EMCCD camera (Figure 1C) and only the
red LEDs were used to excite the exposed cardiac tissue during dye-
loading procedures (see Supplementary material online, Movie S7).
Efficacy was assessed qualitatively by looking at live fluorescence videos
of the dye-loaded cardiac tissue at high frame rates (300 fps) and detect-
ing sudden decreases in emission intensity corresponding to the phase-
zero depolarization (see Supplementary material online, Movie S8).
Figure 2 Excitation ratiometry of di-4-ANBDQBS and di-4-ANEQ(F)PTEA in the isolated pig heart with excitation-contraction uncoupled. (A) Flow-
chart of optical mapping experiments represented in the figure. (B) Action potential (AP) signals at sites ‘a’, ‘b’ (di-4-ANBDQBS), ‘c,’ and ‘d’ (di-4-
ANEQ(F)PTEA) on the epicardial surface of the heart obtained by exciting the tissue at 480 nm (numerator; blue) and 640 nm (denominator; red).
The ratio of the numerator to denominator signal is shown in black (stimulation site: red square pulse). (C) Time series of normalized transmembrane
voltage fluorescence intensity maps (using ratio signals) during point electrical pacing (500 ms CL) (di-4-ANBDQBS) and sinus rhythm (di-4-
ANEQ(F)PTEA). (D) DF maps during VF using di-4-ANBDQBS (left panels) and di-4-ANEQ(F)PTEA (right panels). Sample AP signals and DF values are
shown at sites ‘a’ (di-4-ANBDQBS) and ‘b’ (di-4-ANEQ(F)PTEA). AP signals illustrate irregular electrical activity and alterations in emission intensity of
opposite polarity. Signals are in arbitrary fluorescence units. DF, dominant frequency; LV, left ventricle; RV, right ventricle; SR, sinus rhythm.



















..Dye-loading was possible both in the absence of and in the presence of
regular coronary blood flow (Figure 4A and B). However, coronary occlu-
sion during dye loading led to VF requiring direct-current shock in three
out of five pigs (see experimental flow-chart in Figure 5A). Therefore,
subsequent experiments were performed using the dye-loading protocol
in the presence of regular coronary blood flow. Importantly, although both
di-4-ANBDQBS and di-4-ANEQ(F)PTEA loaded easily ex vivo, we found
that di-4-ANEQ(F)PTEA loaded significantly more easily in vivo.
Figure 3 Ex vivo optical fibre-based excitation ratiometry of di-4-ANBDQBS and di-4-ANEQ(F)PTEA in contracting tissue. (A) Flow-chart of optical
mapping experiments represented in the figure. (B) 2D optical-fibre array pressed against the surface of a Langendorff-perfused pig heart (left panel).
Numerator (blue), denominator (red) and ratio (black) action potential signals from two sample fibres using di-4-ANBDQBS (middle panel), and before
and after blebbistatin using di-4-ANEQ(F)PTEA (right panel). (C) Sample activation maps illustrating propagation of the wavefront (left panel) and APD
maps (right panel) before and after blebbistatin in the perfusate. Stimulation sites (black square pulses) are shown relative to the fibre array. (D, E) APD
(D) and CV (E) comparisons (Wilcoxon Signed Rank test) before and after blebbistatin in the perfusate. Five hearts and four sample fibres per heart were
included in the analysis. (F) AP signals from a 500mm fibre, demonstrating motion artefact cancellation. Signals are in arbitrary fluorescence units. APD, ac-
tion potential duration; CV, conduction velocity; LAT, local activation time.
















































..3.4 Voltage ratiometry in vivo enables
optical mapping of VF dynamics
Without excitation-contraction uncoupling, motion of the contracting
heart was expectedly substantial. To image the propagation of activation
fronts, electrical stimulation was performed at relatively high frequencies
(300 ms CL) to reduce motion (an experimental flow-chart is shown in
Figure 5A). Although the tissue translation accompanying each contrac-
tion led to substantial motion artefacts, ratiometry alone using both di-4-
ANBDQBS and di-4-ANEQ(F)PTEA could significantly reduce these
artefacts (Figure 5B), permitting the tracking of wavefront propagation
and the generation of activation maps from the stimulation site (Figure 5C
and D; see Supplementary material online, Movies S9 and S10). During
VF, however, motion was significantly reduced and ratiometric optical
mapping eliminated most of the motion artefacts, which enabled the gen-
eration of DF maps (Figure 5E). Moreover, voltage ratiometry also
allowed high-resolution tracking of VF dynamics (see Supplementary ma-
terial online, Movie S11 and S12). DF analysis showed significantly higher
DFmax values in ex vivo Langendorff-perfused hearts (n = 5) compared
with in vivo episodes (n = 4) upon VF induction [9.3 (8.5–10.6) Hz vs. 7.4
(6.4–8.7) Hz; P = 0.032]. Conversely, in vivo episodes showed a statistical
trend to a higher singularity point density upon VF induction [0.77 (0.53–
0.98)% vs. 0.41 (0.36–0.57)%; P = 0.064, Figure 5F and see Supplementary
material online, Movies S13 and S14].
3.5 Optical fibres enable in vivo optical
mapping of organized rhythms
Although ratiometry substantially reduces motion artefacts (Figure 5B),
far-field imaging of organized rhythms cannot generate accurate APD
maps due to translational motion. Therefore, the fibre-based imaging
system outlined in Figure 1B and D was constructed to obtain AP record-
ings during organized electrical activity. An experimental flow-chart is
shown in Figure 6A. The distal optical-fibre ends were pressed against the
heart surface (Figure 6B and see Supplementary material online, Movie
S5) to measure wave propagation dynamics and APs in strongly con-
tracting hearts during pacing. Sample numerator-, denominator-, and
ratio-action-potential signals using both di-4-ANBDQBS and di-4-
ANEQ(F)PTEA are shown in Figure 6B. Sample activation and APD maps
are also shown in Figure 6C. Synchronized ECG and blood pressure
measurements could be also obtained during in vivo optical mapping (see
Supplementary material online, Figure S2).
Ratiometric optical-fibre data during pacing at 400 ms CL in vivo
showed significantly faster CV [120 (63–138) cm/s vs. 51 (41–64) cm/s;
P = 0.032, Figure 6D] and a statistical trend to longer APD [APD90 242
(217–254) ms vs. 192 (182–233) ms; P = 0.095, Figure 6D] compared
with ex vivo measurements before blebbistatin perfusion.
To quantify the signal decay in vivo, we measured the signal-to-noise
ratio [SNR= (AP Amplitude)/(SD during diastolic intervals)] decay rate
Figure 4 In vivo dye loading. (A) Left panel: Brightfield image of a sample heart loaded using balloon occlusion of the LAD coronary artery. Right panel:
Fluorescence image of the same heart using red LED excitation (640 nm). (B) Left panel: Brightfield image of another sample heart with the dye-loading
region delineated by the black dashed line. Right panels: Snapshots of a fluorescence coronary angiogram recorded at 300 fps with a high-resolution
CMOS camera during dye loading in the presence of regular coronary blood flow.
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Figure 5 In vivo optical mapping of paced rhythms and ventricular fibrillation (VF). (A) Flow-chart of optical mapping experiments represented in the fig-
ure. (B) Action potential (AP) signals at sites ‘a’, ‘b’ (di-4-ANBDQBS), ‘c,’ and ‘d’ (di-4-ANEQ(F)PTEA) on the epicardial surface of the heart obtained by
exciting the tissue at 480 nm (numerator; blue) and640 nm (denominator; red). The ratio of the numerator to denominator signal is shown in black
(stimulation sites: red square pulses). Despite the substantial motion, ratiometric optical mapping could detect the AP upstroke. (C, D) Time series of nor-
malized transmembrane voltage fluorescence intensity maps and activation map (using ratio signals) during point electrical pacing (300 ms CL). (E) DF
maps during VF using di-4-ANBDQBS (left panels) and di-4-ANEQ(F)PTEA (right panels). Sample AP signals and DF values are shown at sites ‘a’ (di-4-
ANBDQBS) and ‘b’ (di-4-ANEQ(F)PTEA). AP signals illustrate irregular electrical activity during VF. Signals are in arbitrary fluorescence units. (F) DF and
SPD comparisons (Mann–Whitney U test) between in vivo (n = 4) and ex vivo (n = 5) VF episodes. DF, dominant frequency; LV, left ventricle; RV, right ven-
tricle; SPD, singularity point density; VF, ventricular fibrillation.








































































































over a 50-min period following di-4-ANEQ(F)PTEA injection. Fitting the
data points to a single-term exponential model (Figure 6E), the average
decay rate for four animals was 0.0671± 0.0090 min-1. Reloading with di-
4-ANEQ(F)PTEA showed that the SNR fully recovered (Figure 6F).
Conversely, the SNR decay rate in the Langendorff-perfused heart
was much slower 0.006836 min-1 (see Supplementary material online,
Figure S3).
3.6 Intracoronary di-4-ANBDQBS/di-4-
ANEQ(F)PTEA injection does not induce
toxicity to the vital organs
A flow-chart of the toxicity analyses is shown in Figure 7A. Continuous
ECG monitoring from baseline to 30 min after dye/solvent injection
showed no signs of di-4-ANBDQBS/di-4-ANEQ(F)PTEA-related cardiac
toxicity. Heart rates were stable throughout the recording period in all
three subgroups (see Supplementary material online, Figure S4A).
Flushing with saline before dye/solvent injection showed transient nega-
tive T waves on the ECG, with the heart fully recovering within 1 min.
The same effect was observed during dye/solvent injection (Figure 7B).
ECG intervals (PR, QRS complex, and corrected QT interval) did not
show statistically significant differences among subgroups (Figure 7C and
D; see Supplementary material online, Figure S4B). Invasive blood pres-
sure monitoring revealed transient hypotension (severe in two animals)
after di-4-ANBDQBS injection, which was not observed after di-4-
ANEQ(F)PTEA or solvent injection (Figure 7E).
Cardiac, brain, liver, and kidney biomarkers did not show statistically
significant differences among subgroups nor any signs of overt toxicity at
any time point (Figure 7F and see Supplementary material online, Figure
S5). A very mild increase in Troponin I was observed at 12 and 24 h after
dye/solvent injection, though not reaching the infarct threshold level cur-
rently established for percutaneous interventional procedures
(Figure 7F). Similarly, none of the other blood and plasma biomarkers, so-
dium, potassium, and chlorine levels showed any overt alterations or sta-
tistically significant differences among subgroups (see Supplementary
material online, Figure S6).
Tissue characterization using CMR imaging did not show acute/late
signs of myocardial oedema, scar tissue development nor deterioration
of the left ventricular ejection function in all three subgroups (Figure 7G,
H and see Supplementary material online, Figures S7 and S8).
4. Discussion
Here, we reported measurements of cardiac APs and wave propagation
dynamics in vivo using optical methods, enabling the acquisition of high
spatiotemporal resolution cardiac electrophysiology information. Our
experimental method was applied to a pig model using near-infrared
voltage-sensitive dyes, which were injected percutaneously into the reg-
ular coronary blood flow. The presented series of experiments and dye
toxicity studies support our aim to make in vivo optical mapping a stan-
dard experimental method that can lead to results with strong clinical
implications.
Cardiac optical mapping is primarily based on high-speed fluorescence
imaging or recording of synthetic voltage-sensitive dyes bound to cardio-
myocyte plasma membranes. The high-speed spectral shift due to
changes in transmembrane voltage permits the accurate measurement
of APs.19 Optical mapping provides a number of advantages over con-
ventional extracellular recordings,20 foremost is the ability to directly
track AP propagation at the cellular level, leading to greater spatial
resolution at the tissue level.2,14 However, the motion accompanying
each heart beat affects signal fidelity. This has led to the use of mechani-
cal uncouplers (e.g. blebbistatin), and heart immobilization techniques
during optical mapping experiments. Although some researchers have
reported that 10mM blebbistatin perfusion has no effect on AP morphol-
ogy in rabbit cardiac tissue,21 others have documented significant prolon-
gation of the APD and have speculated decreases in CV at just 5mM
blebbistatin perfusion.22 Furthermore, the use of excitation-contraction
uncouplers like blebbistatin precludes the simultaneous measure of con-
tractility, an important physiological parameter. Our study was not
designed to address the effects of blebbistatin on APD and CV. The ob-
served changes in APD and CV when using blebbistatin might not be a
specific effect of the drug, but rather a consequence of the metabolic
state of the heart when ATP is abundant due to contraction inhibition. In
addition, APD prolongation may be time-dependent (time-matched con-
trol experiments were not performed in our study). The observed de-
crease in CV during pacing may also be a direct effect of APD
prolongation.
Of the imaging methods developed for handling motion artefacts dur-
ing ex vivo optical mapping studies, ratiometry has been shown to signifi-
cantly reduce artefacts in AP signals.23 Its use in vivo has not been
reported to our knowledge. Furthermore, there have been no published
investigations of the ratiometric properties of near-infrared voltage-sen-
sitive dyes developed for blood-perfused cardiac tissue in a clinically rele-
vant animal model like the adult pig. Though di-4-ANEPPS was used in
the first and only reported in vivo optical mapping study in a large mam-
mal model, ratiometry was not employed and green light was used for
dye excitation, which is strongly absorbed by blood.24 Unlike di-4-
ANEPPS, near-infrared voltage-sensitive dyes have optimal excitation
wavelengths in cardiac tissue beyond the absorption maximum of hae-
moglobin and other endogenous chromophores, making its use optimal
for deeper tissue probing and optical mapping in blood-perfused myo-
cardium.18,25 Importantly, our investigation demonstrates that both di-4-
ANBDQBS and di-4-ANEQ(F)PTEA display spectral shifts in excitation
spectra, with voltage dependence of opposite polarity at 480 nm vs.
640 nm, corresponding, respectively, to the blue and red wings of the
dye excitation spectrum.
Past studies have also investigated the ratiometric properties of di-4-
ANEPPS ex vivo in the adult pig myocardium, although the technique was
not translated to an in vivo setting and utilized a more costly implementa-
tion requiring two cameras/detectors (i.e. emission ratiometry).26 The
optical mapping systems developed in this study used excitation ratiome-
try, a single camera and low-cost LED light sources. The use of different
excitation wavelengths in excitation ratiometry, though, leads to differ-
ences in photon absorption and scattering in cardiac tissue.27 Our ap-
proach enabled us to identify propagation wave fronts and detect APs in
vivo under different motion conditions. Furthermore, newer dyes, like
the di-4-ANBDQBS and di-4-ANEQ(F)PTEA dyes used in this study,
have higher voltage sensitivity and are more resistant to photobleaching
and cellular internalization.18
The open-chest pig animal model, though critical to the development
of in vivo optical mapping methods and relevant to studying complex pat-
terns of propagation in easily exposed epicardial tissue, involves an inva-
sive procedure that limits its translational impact. Our development and
validation of an optical-fibre mapping system was an initial attempt at en-
abling closed chest procedures. Further development of optical-fibre
mapping systems would not only simplify certain aspects of in vivo experi-
ments and instrumentation, it would have direct application to clinical
settings. The first and seminal in vivo optical mapping study in the late












), Irene Aguero on 11 Septem
ber 2019
Figure 6 In vivo optical-fibre fluorescence recordings. (A) Flow-chart of optical mapping experiments represented in the figure. (B) Positioning of the
optical-fibre array during an experimental procedure (left panel). Sample numerator (blue), denominator (red) and ratio (black) AP signals at 500 and
250 ms BDCLs using di-4-ANBDQBS (middle panel) and di-4-ANEQ(F)PTEA (right panel). (C) Sample activation maps illustrating propagation of the
wavefront (right panels) and APD maps (left panels) at 500 and 250 ms BDCLs using di-4-ANEQ(F)PTEA. Stimulation sites (black square pulses) are
shown relative to the fibre array. (D) APD and CV comparisons (Mann–Whitney U test) between in vivo (n = 5) and ex vivo (n = 5) hearts (four sample
fibres per heart). (E, F) Two sample SNR decays (E, F) and reloading (F) with di-4-ANEQ(F)PTEA. Signals are in arbitrary fluorescence units. APD, action
potential duration; BDCL, basic drive cycle length; CV, conduction velocity; LAT, local activation time; SNR, signal-to-noise ratio.































..1990s also used optical fibres to record APs and propagation dynamics.
The voltage-sensitive dye di-4-ANEPPS and a canine animal model were
used to demonstrate the feasibility of translating ex vivo optical mapping
techniques to an in vivo setting.28 Other than one study in a rat animal
model,29 there has been no subsequent published work further develop-
ing in vivo optical mapping, which we presume was due to technical limita-
tions. For instance, the rat study used a non-physiological
cardiopulmonary bypass circuit to offload the blood-pumping work to
an external pump. Although this approach would permit the use of heart
immobilization techniques, its potential translational application would
be very limited and simultaneous measurement of contractility would
not be possible. Here, we reported that these technical limitations no
longer exist and high-performance optical mapping catheter development
is now feasible.25,30,31 Complemented with the development of higher-
performance voltage-sensitive dyes and dye-loading procedures,17 in vivo
optical mapping has the potential to open the door to a new era of high-
performance mapping in the cardiac electrophysiology field.
In vivo intracoronary dye injection and loading naturally raises con-
cerns regarding toxicity in the heart and other vital organs. Indeed, previ-
ous reports using di-4-ANEPPS in isolated cardiomyocytes have
documented illumination-induced phototoxicity that could be decreased
by adding the antioxidant catalase, suggesting the involvement of a reac-
tive oxygen species during induced-photodynamic damage.32 Though
phototoxicity appears to be less pronounced in whole heart
Figure 7 Dye toxicity assessment. (A) Flow-chart of the toxicity protocol. (B) Sample ECG tracings (lead V2) during the monitoring period in the three
subgroups. (C–F) QRS complex duration (C), corrected QT interval (D), mean blood pressure (E), and Troponin I (cTnI) (F) comparisons among sub-
groups. The infarct threshold criterion after percutaneous coronary interventions is represented with a brown dashed line (F). (G, H) Comparisons of T2
GraSE (G) and post-contrast T1 mapping (H) sequences among subgroups. Data are represented as mean and standard deviation, but in (E), standard
errors of the means are shown because of the large variability in blood pressure measurements. Physiological ranges are represented with green dashed
lines. Blue circles: solvent (n = 4). Red squares: di-4-ANBDQBSþsolvent (n = 4). Purple diamonds: di-4-ANEQ(F)PTEAþsolvent (n = 4). # and † indicate
P-values for two-way repeated measures ANOVA of solvent vs. di-4-ANBDQBS (#), and solvent vs. di-4-ANEQ(F)PTEA (†).








































































































preparations, the use of the newer dyes has been shown to lead to much
smaller effects on APD than the older di-4-ANEPPS dye.33 But neither
isolated cell nor Langendorff-perfused heart preparations can provide
toxicity data that can be extrapolated to the in vivo setting. As such, we
conducted a comprehensive toxicity study, in which intracoronary dye
injection did not induce acute nor subacute signs of damage to vital
organs (long-term illumination-induced phototoxicity was not tested).
Moreover, we did not observe dye-induced pro-arrhythmia during injec-
tion. The risk of VF was only present when dye injection was performed
in the absence of regular coronary blood flow using balloon occlusion.
Severe transient hypotension was the main effect observed during di-4-
ANBDQBS injection, though it varied from animal to animal.
Hypotension was not observed using di-4-ANEQ(F)PTEA.
We acknowledge that some limitations are still present. Di-4-
ANBDQBS, di-4-ANEQ(F)PTEA, and other newly developed near-infrared
dyes must be further characterized in both pig and human cardiac tis-
sues.14,34,35 Both optical spectra and toxicity profiles must be established for
existing candidate dyes while new voltage-sensitive dyes are specifically de-
veloped for in vivo optical mapping. Improvements need to be made in
voltage-sensitivity, solubility in aqueous solvents and tissue loading speed.
Though toxicity profiling in humans would require approval by international
regulatory agencies, recent work using the FDA-approved Indocyanine
Green as a voltage-sensitive dye in isolated rabbit hearts may help lower
boundaries to testing optimized voltage-sensitive dyes in humans.36
Further developments in instrumentation are also needed. For instance,
catheters capable of measuring complementary electrical and optical signals
may prove useful for different myocardial substrates with complex electrical
signal interpretation.10 The in vivo optical mapping techniques reported here,
however, can already be used to investigate complex VF episodes after myo-
cardial infarction in clinically relevant animal models. The latter would be diffi-
cult to perform with current electrical mapping technologies.11,37 However,
voltage ratiometry during far-field in vivo imaging of organized rhythms can-
not generate accurate APD nor repolarization maps without implementing
further signal processing and motion tracking routines.38,39
In conclusion, we have demonstrated an experimental method for
performing in vivo optical mapping in a pig animal model, addressing issues
related to motion artefacts, dye loading, and toxicity. Further develop-
ment and experimentation may lead to a significant and clinically relevant
advance in high resolution in vivo mapping of cardiac electrophysiology.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
Acknowledgements
We are grateful for technical support provided by the animal facility at
CNIC. We also thank the Richard D. Berlin Center for Cell Analysis and
Modeling.
Conflict of interest: P.L. is both an owner and employee of Essel
Research and Development Inc. P.Y. is both an owner and employee
and L.M.L. is an owner of Potentiometric Probes, LLC. The other
authors report no conflicts.
Funding
The CNIC is supported by the Ministry of Science, Innovation and
Universities and the Pro CNIC Foundation. The CNIC is a Severo Ochoa
Center of Excellence (SEV-2015-0505). This study was supported by grants
from Fondo Europeo de Desarrollo Regional (CB16/11/00458), the Spanish
Ministry of Science, Innovation and Universities (SAF2016-80324-R, PI16/
02110, and DTS17/00136), and by the European Commission (ERA-CVD
Joint Call [JTC2016/APCIN-ISCIII-2016], grant#AC16/00021). The study was
also partially supported by the Fundación Interhospitalaria para la
Investigación Cardiovascular (FIC) and the Heart Rhythm section of the
Spanish Society of Cardiology. The work at the University of Connecticut
was supported by grant EB001963 from the National Institutes of Health.
References
1. Neher E, Sakmann B. Single-channel currents recorded from membrane of dener-
vated frog muscle fibres. Nature 1976;260:799–802.
2. Gray RA, Jalife J, Panfilov AV, Baxter WT, Cabo C, Davidenko JM, Pertsov AM,
Hogeweg P, Winfree AT. Mechanisms of cardiac fibrillation. Science 1995;270:
1222–1223.
3. Horowitz LN, Harken AH, Kastor JA, Josephson ME. Ventricular resection guided by
epicardial and endocardial mapping for treatment of recurrent ventricular tachycar-
dia. N Engl J Med 1980;302:589–593.
4. Narayan SM, Baykaner T, Clopton P, Schricker A, Lalani GG, Krummen DE,
Shivkumar K, Miller JM. Ablation of rotor and focal sources reduces late recurrence
of atrial fibrillation compared with trigger ablation alone: extended follow-up of the
CONFIRM trial. J Am Coll Cardiol 2014;63:1761–1768.
5. Marchlinski FE, Haffajee CI, Beshai JF, Dickfeld TM, Gonzalez MD, Hsia HH, Schuger
CD, Beckman KJ, Bogun FM, Pollak SJ, Bhandari AK. Long-term success of irrigated
radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval
THERMOCOOL VT trial. J Am Coll Cardiol 2016;67:674–683.
6. Piers SR, Tao Q, de Riva Silva M, Siebelink HM, Schalij MJ, van der Geest RJ,
Zeppenfeld K. CMR-based identification of critical isthmus sites of ischemic and noni-
schemic ventricular tachycardia. JACC Cardiovasc Imaging 2014;7:774–784.
7. Sasaki T, Miller CF, Hansford R, Yang J, Caffo BS, Zviman MM, Henrikson CA, Marine
JE, Spragg D, Cheng A, Tandri H, Sinha S, Kolandaivelu A, Zimmerman SL, Bluemke
DA, Tomaselli GF, Berger RD, Calkins H, Halperin HR, Nazarian S. Myocardial struc-
tural associations with local electrograms: a study of postinfarct ventricular tachycar-
dia pathophysiology and magnetic resonance-based noninvasive mapping. Circ
Arrhythm Electrophysiol 2012;5:1081–1090.
8. Ndrepepa G, Caref EB, Yin H, el-Sherif N, Restivo M. Activation time determination
by high-resolution unipolar and bipolar extracellular electrograms in the canine heart.
J Cardiovasc Electrophysiol 1995;6:174–188.
9. Haws CW, Lux RL. Correlation between in vivo transmembrane action potential
durations and activation-recovery intervals from electrograms. Effects of interven-
tions that alter repolarization time. Circulation 1990;81:281–288.
10. Anter E, Tschabrunn CM, Buxton AE, Josephson ME. High-resolution mapping of
postinfarction reentrant ventricular tachycardia: electrophysiological characterization
of the circuit. Circulation 2016;134:314–327.
11. Kuklik P, Zeemering S, Maesen B, Maessen J, Crijns HJ, Verheule S, Ganesan AN,
Schotten U. Reconstruction of instantaneous phase of unipolar atrial contact electro-
gram using a concept of sinusoidal recomposition and Hilbert transform. IEEE Trans
Biomed Eng 2015;62:296–302.
12. Lee P, Calvo CJ, Alfonso-Almazan JM, Quintanilla JG, Chorro FJ, Yan P, Loew LM,
Filgueiras-Rama D, Millet J. Low-cost optical mapping systems for panoramic imaging
of complex arrhythmias and drug-action in translational heart models. Sci Rep 2017;7:
43217.
13. Herron TJ, Lee P, Jalife J. Optical imaging of voltage and calcium in cardiac cells & tis-
sues. Circ Res 2012;110:609–623.
14. Zhao J, Hansen BJ, Wang Y, Csepe TA, Sul LV, Tang A, Yuan Y, Li N, Bratasz A,
Powell KA, Kilic A, Mohler PJ, Janssen PML, Weiss R, Simonetti OP, Hummel JD,
Fedorov VV. Three-dimensional integrated functional, structural, and computational
mapping to define the structural “fingerprints” of heart-specific atrial fibrillation driv-
ers in human heart ex vivo. J Am Heart Assoc 2017;6:e005922.
15. Filgueiras-Rama D. Sympathetic innervation and cardiac arrhythmias. In DP Zipes, J
Jalife, WG Stevenson (eds). Cardiac Electrophysiology: From Cell to Bedside. 7th ed.
Philadelphia, USA: Elsevier; 2017.
16. Li F, Yuan Y. Meta-analysis of the cardioprotective effect of sevoflurane versus pro-
pofol during cardiac surgery. BMC Anesthesiol 2015;15:128.
17. Yan P, Acker CD, Zhou WL, Lee P, Bollensdorff C, Negrean A, Lotti J, Sacconi L,
Antic SD, Kohl P, Mansvelder HD, Pavone FS, Loew LM. Palette of fluorinated
voltage-sensitive hemicyanine dyes. Proc Natl Acad Sci USA 2012;109:20443–20448.
18. Matiukas A, Mitrea BG, Qin M, Pertsov AM, Shvedko AG, Warren MD, Zaitsev AV,
Wuskell JP, Wei MD, Watras J, Loew LM. Near-infrared voltage-sensitive fluorescent
dyes optimized for optical mapping in blood-perfused myocardium. Heart Rhythm
2007;4:1441–1451.
19. Girouard SD, Laurita KR, Rosenbaum DS. Unique properties of cardiac action poten-
tials recorded with voltage-sensitive dyes. J Cardiovasc Electrophysiol 1996;7:
1024–1038.















































.20. Hooks DA, LeGrice IJ, Harvey JD, Smaill BH. Intramural multisite recording of trans-
membrane potential in the heart. Biophys J 2001;81:2671–2680.
21. Fedorov VV, Lozinsky IT, Sosunov EA, Anyukhovsky EP, Rosen MR, Balke CW,
Efimov IR. Application of blebbistatin as an excitation-contraction uncoupler for elec-
trophysiologic study of rat and rabbit hearts. Heart Rhythm 2007;4:619–626.
22. Brack KE, Narang R, Winter J, Ng GA. The mechanical uncoupler blebbistatin is asso-
ciated with significant electrophysiological effects in the isolated rabbit heart. Exp
Physiol 2013;98:1009–1027.
23. Knisley SB, Justice RK, Kong W, Johnson PL. Ratiometry of transmembrane voltage-
sensitive fluorescent dye emission in hearts. Am J Physiol Heart Circ Physiol 2000;279:
H1421–H1433.
24. Gush RJ, King TA. Discrimination of capillary and arterio-venular blood flow in skin
by laser Doppler flowmetry. Med Biol Eng Comput 1991;29:387–392.
25. Singh-Moon RP, Marboe CC, Hendon CP. Near-infrared spectroscopy integrated
catheter for characterization of myocardial tissues: preliminary demonstrations to
radiofrequency ablation therapy for atrial fibrillation. Biomed Opt Express 2015;6:
2494–2511.
26. Tai DC, Caldwell BJ, LeGrice IJ, Hooks DA, Pullan AJ, Smaill BH. Correction of mo-
tion artifact in transmembrane voltage-sensitive fluorescent dye emission in hearts.
Am J Physiol Heart Circ Physiol 2004;287:H985–H993.
27. Bishop MJ, Plank G. Simulating photon scattering effects in structurally detailed ven-
tricular models using a Monte Carlo approach. Front Physiol 2014;5:338.
28. Dillon SM, Kerner TE, Hoffman J, Menz V, Li KS, Michele JJ. A system for in-vivo car-
diac optical mapping. IEEE Eng Med Biol Mag 1998;17:95–108.
29. Lee P, Taghavi F, Yan P, Ewart P, Ashley EA, Loew LM, Kohl P, Bollensdorff C,
Woods CE. In situ optical mapping of voltage and calcium in the heart. PLoS One
2012;7:e42562.
30. Herranz D, Lloret J, Jimenez-Valero S, Rubio-Guivernau JL, Margallo BE. Novel cathe-
ter enabling simultaneous radiofrequency ablation and optical coherence reflectome-
try. Biomed Opt Express 2015;6:3268–3275.
31. Bourier F, Gianni C, Dare M, Deisenhofer I, Hessling G, Reents T, Mohanty S, Trivedi
C, Natale A, Al-Ahmad A. Fiberoptic contact-force sensing electrophysiological cath-
eters: how precise is the technology? J Cardiovasc Electrophysiol 2017;28:109–114.
32. Schaffer P, Ahammer H, Muller W, Koidl B, Windisch H. Di-4-ANEPPS causes photo-
dynamic damage to isolated cardiomyocytes. Pflugers Arch 1994;426:548–551.
33. Kanaporis G, Martisien _e I, Jurevicius J, Vosyliut _e R, Navalinskas A, Treinys R, Matiukas
A, Pertsov AM. Optical mapping at increased illumination intensities. J Biomed Opt
2012;17:96007–96001.
34. Fedorov VV, Glukhov AV, Chang R, Kostecki G, Aferol H, Hucker WJ, Wuskell JP,
Loew LM, Schuessler RB, Moazami N, Efimov IR. Optical mapping of the isolated
coronary-perfused human sinus node. J Am Coll Cardiol 2010;56:1386–1394.
35. Fedorov VV, Ambrosi CM, Kostecki G, Hucker WJ, Glukhov AV, Wuskell JP, Loew
LM, Moazami N, Efimov IR. Anatomic localization and autonomic modulation of
atrioventricular junctional rhythm in failing human hearts. Circ Arrhythm Electrophysiol
2011;4:515–525.
36. Martisiene I, Macianskiene R, Treinys R, Navalinskas A, Almanaityte M, Karciauskas D,
Kucinskas A, Grigaleviciute R, Zigmantaite V, Benetis R, Jurevicius J. Voltage-sensitive
fluorescence of indocyanine green in the heart. Biophys J 2016;110:723–732.
37. Vidmar D, Krummen DE, Hayase J, Narayan SM, Ho G, Rappel WJ. Spatiotemporal
progression of early human ventricular fibrillation. JACC Clin Electrophysiol 2017;3:
1437–1446.
38. Quintanilla JG, Moreno J, Archondo T, Usandizaga E, Molina-Morúa R, Rodrı́guez-
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